What is BiVACOR?
Founded in 2008, BiVACOR operates at the intersection of mechanical engineering and life sciences. The company specializes in the development of a total artificial heart, a breakthrough technology designed to provide a durable, long-term solution for patients suffering from end-stage heart failure. With a multidisciplinary team of world-class engineers and medical specialists, BiVACOR maintains a robust collaborative network that spans international borders, ensuring that its technological advancements are grounded in both rigorous scientific research and practical clinical application. Their market position is defined by a commitment to high-stakes innovation in the cardiovascular space, aiming to redefine the standard of care for patients who have exhausted conventional treatment options.
How much funding has BiVACOR raised?
BiVACOR has raised a total of $22M across 2 funding rounds:
Grant
$3M
Series B
$19M
Grant (2021): $3M with participation from National Heart, Lung, and Blood Institute at the U.S. National Institute of Health
Series B (2021): $19M led by OneVentures and Cormorant Asset Management
Key Investors in BiVACOR
Cormorant Asset Management
A prominent life sciences investment firm focused on fundamental scientific principles, providing capital to innovative private and public biotech companies.
OneVentures
An Australian-based venture capital firm that specializes in scaling high-growth technology and healthcare companies through strategic financial support.
National Heart, Lung, and Blood Institute
A division of the U.S. National Institutes of Health that provides critical grant funding to support groundbreaking research in cardiovascular and pulmonary health.
What's next for BiVACOR?
With the recent capital injection, BiVACOR is poised to enter a critical phase of clinical validation and operational scaling. The strategic focus will likely shift toward finalizing the regulatory requirements necessary for human trials and expanding manufacturing capabilities to meet anticipated demand. As the company moves deeper into its Series B lifecycle, the emphasis will remain on demonstrating the long-term efficacy and safety of its artificial heart technology. Investors and industry stakeholders will be closely monitoring the firm's progress as it transitions from a research-heavy entity to a commercial-ready medical device manufacturer, potentially setting a new benchmark for innovation in the global cardiovascular market.
See full BiVACOR company page
